The effects of silencing EDF-1 in human endothelial cells

Atherosclerosis

Volumn 211, Issue 1, 2010, Pages 55-60

  Leidi, Marzia ^a   Mariotti, Massimo ^a   Maier, Jeanette A M ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

EDF 1; Endothelial; NO

Indexed keywords

CALMIDAZOLIUM; CALMODULIN; CALMODULIN BINDING PROTEIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROTEIN EDF 1; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; EDF1 PROTEIN, HUMAN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; IMIDAZOLE DERIVATIVE; NOS3 PROTEIN, HUMAN;

ARTICLE; CELL ORGANELLE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME RELEASE; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING; CELL CULTURE; DRUG EFFECTS; GENETICS; METABOLISM; UMBILICAL VEIN;

CALMODULIN-BINDING PROTEINS; CELL PROLIFERATION; CELLS, CULTURED; DOWN-REGULATION; ENDOTHELIAL CELLS; GENE SILENCING; HUMANS; IMIDAZOLES; NITRIC OXIDE SYNTHASE TYPE III; UMBILICAL VEINS; UP-REGULATION;

EID: 77954314344     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.01.022     Document Type: Article

References (24)

1. Cines D.B., Pollak E.S., Buck C.A., et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998, 91:3527-3561.
2. Mariotti M., Maier J.A.M. Angiogenesis: an overview. New frontiers in angiogenesis 2006, 1-29. Springer Inc., The Netherlands. R. Forough (Ed.).
3. Vanhoutte P.M. Endothelial dysfunction: the first step toward coronary arteriosclerosis. Circ J 2009, 73(4):595-601.
4. Erusalimski J.D. Vascular endothelial senescence: from mechanisms to pathophysiology. J Appl Physiol 2009, 106:326-332.
5. Bernardini D., Ballabio E., Mariotti M., Maier J.A.M. Differential expression of EDF-1 and endothelial nitric oxide synthase by proliferating, quiescent and senescent microvascular endothelial cells. Biochim Biophys Acta-Mol Cell Res 2005, 1745(2):265-272.
6. Dragoni I., Mariotti M., Consalez G.G., Soria M., Maier J.A.M. EDF-1, a novel gene product down-regulated in human endothelial cell differentiation. J Biol Chem 1998, 273:31119-31124.
7. Mariotti M., Avon E., De Benedictis L., Maier J.A.M. Interaction between endothelial differentiation-related factor-1 and calmodulin in vitro and in vivo. J Biol Chem 2000, 275:24047-24051.
8. Ballabio E., Mariotti M., De Benedictis L., Maier J.A.M. The dual role of EDF-1 in the cytosol and in the nucleus: modulation by PKA. Mol Cell Life Sci 2004, 61:1069-1074.
9. Brendel C., Gelman L., Auwerx J. Multiprotein bridging factor-1 (MBF-1) is a cofactor for nuclear receptors that regulate lipid metabolism. Mol Endocrinol 2002, 16:2065-2076.
10. Leidi M., Mariotti M., Maier J.A.M. Transcription coactivator EDF-1 is required for PPARγ-stimulated adipogenesis. Cell Mol Life Sci 2009, 66:2733-2742.
11. Bolognese F., Pitarque-Martì M., Lo Cicero V., Mantovani R., Maier J.A.M. Involvement of NFY and SP1 in the basal transcription of the human EDF-1 gene. Gene 2006, 374:87-95.
12. 2+-transport ATPase and brain phosphodiesterase by activators and inhibitors. Biochem J 1982, 207(3):541-548.
13. Babaei S., Teichert-Kuliszewska K., Monge J.C., et al. Role of nitric oxide in the angiogenic response in vitro to basic fibroblast growth factor. Circ Res 1998, 82(9):1007-1015.
14. Fleming I., Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol 2003, 284(1):R1-12.
15. Albright S.R., Tjian R. TAFs revisited: more data reveal new twists and confirm old ideas. Gene 2000, 242:1-13.
16. Villalonga P., López-Alcalá C., Chiloeches A., et al. Calmodulin prevents activation of Ras by PKC in 3T3 fibroblasts. J Biol Chem 2002, 277(40):37929-37935.
17. Rasmussen C.D., Means A.R. Calmodulin is required for cell-cycle progression during G1 and mitosis. EMBO J 1989, 8(1):73-82.
18. Bredt D.S., Snyder S.H. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc Natl Acad Sci USA 1990, 87(2):682-685.
19. van Haperen R., de Waard M., van Deel E., et al. Reduction of blood pressure, plasma cholesterol, and atherosclerosis by elevated endothelial nitric oxide. J Biol Chem 2002, 27:48803-48807.
20. Florio T., Morini M., Villa V., et al. Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. Endocrinology 2003, 144(4):1574-1584.
21. Ziche M., Morbidelli L., Masini E., et al. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest 1994, 94(5):2036-2044.
22. Tonnesen M.G., Feng X., Clark R.A. Angiogenesis in wound healing. J Invest Dermatol Symp Proc 2000, 5(December (1)):40-46.
23. Shaikh F.M., Callanan A., Kavanagh E.G., et al. Fibrin: a natural biodegradable scaffold in vascular tissue engineering. Cells Tissues Organs 2008, 188(4):333-346.
24. Kniazeva E., Putnam A.J. Endothelial cell traction and ECM density influence both capillary morphogenesis and maintenance in 3-D. Am J Physiol Cell Physiol 2009, 297(1):C179-C187.